Histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step  registration
Histopathological evidence of glioblastoma or gliosarcoma, World Health Organization (WHO) grade IV
Must have pathologically documented, and definitively diagnosed World Health Organization (WHO) grade , glioblastoma
Histological confirmation of supratentorial glioblastoma (also known as astrocytoma grade IV, gliosarcoma) amenable to surgical resection =<  days prior to registration
Have pathologically-proven GB, gliosarcoma (World Health Organization [WHO] IV), or anaplastic astrocytoma (WHO III) in recurrence after treatment with bevacizumab
Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
Newly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcoma
Histopathologically proven newly-diagnosed, supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will also be eligible if the original histology was lower grade glioma and there is suspected transformation to glioblastoma based on imaging findings; if the final pathology report after resection fails to confirm recurrent glioblastoma or gliosarcoma, the subject will be followed for adverse events (AEs) and survival, but excluded for other primary and secondary objective analysis; the subject will be replaced
PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Have histologically confirmed World Health Organization grade IV glioma (glioblastoma or gliosarcoma)
PHASE I: Have histologically confirmed World Health Organization WHO grade IV glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma)
Histopathologically confirmed glioblastoma or gliosarcoma (WHO Grade IV) confirmed by local pathology tissue screening.
Histologically confirmed glioblastoma multiforme, World Health Organization (WHO) grade IV astrocytoma
Histologic diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV)
Newly diagnosed glioblastoma (GBM) histologically proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma.
Newly diagnosed, histologically-confirmed supratentorial World Health Organization (WHO) grade IV gliomas including glioblastoma (all variants) and gliosarcoma.
Have histologically confirmed World Health Organization grade IV glioma (glioblastoma [GB] or gliosarcoma).
Newly diagnosed histologically confirmed unmethylated glioblastoma multiforme (World Health Organization [WHO] grade IV). Patients with secondary glioblastoma, in particular those who are IDH or IDH mutant, will not be excluded. Unmethylated MGMT must be confirmed by a polymerase chain reaction (PCR)-based assay.
Histologically-confirmed intracranial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) with evidence of clinical and radiographic (computed tomography [CT] or MRI brain) tumor progression (need not be biopsy proven)
Pathologically confirmed World Health Organization (WHO) grade IV glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma) with adequate tumor material for genomic sequencing; participants will be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis of glioblastoma or its variants was made, and they received no prior therapy other than surgery
Histopathologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) following either a surgical resection or biopsy
d. Glioblastoma -Enrollment Completed Have histologically confirmed World Health Organization Grade IV malignant glioma (glioblastoma).
Histologic documentation: newly diagnosed World Health Organization (WHO) grade IV intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT PERMITTED in this study if they are pq codeleted; sites submitting GBM with oligodendroglial features will be asked to provide results of p/q codeletion status
Confirmation by central pathology review of WHO grade IV glioblastoma or gliosarcoma
Newly diagnosed histologically confirmed glioblastoma multiforme (World Health Organization [WHO] grade IV); patients with secondary glioblastoma, in particular those who are IDH or IDH mutant, will not be excluded
Patients must have histologic verifications of a glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri (World Health Organization [WHO] grade III or IV glioma with diffuse parenchymal and/or leptomeningeal involvement), or gliosarcoma at the time of study enrollment
Pathologically confirmed diagnosis of glioblastoma multiforme (GBM); or World Health Organization (WHO) grade IV (gliosarcoma)
Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or gliosarcoma); participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made
Patients must have tissue confirmation of high grade (World Health Organization [WHO] grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with primitive neuroectodermal tumor (PNET) features
Histological diagnosis of: glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) adapted recursive partitioning analysis (RPA) class III, IV, or V
Patients with histologically proven supratentorial glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV astrocytoma) will be eligible for this protocol; patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or gliosarcoma is made prior to any definitive treatment (radiotherapy, chemotherapy)
GBM patients only (enrollment plan )\r\n* Histologically confirmed glioblastoma multiforme World Health Organization (WHO) grade III-IV with recurrent or progressive disease after standard therapy\r\n* Age  years and older
Patients with histologically proven supratentorial WHO grade IV glioma (glioblastoma or gliosarcoma) will be eligible for the study.
Histologically confirmed GBM or World Health Organization (WHO) Grade IV variants (gliosarcoma, glioblastoma with oligodendroglial features, or giant cell glioblastoma).
Patients must have histologically confirmed diagnosis of a recurrent/progressive World Health Organization (WHO) grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma)
Participants must have histologically or cytologically confirmed newly-diagnosed glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV/IV) and be planning to undergo standard chemoradiation treatment